Security
VIRX · Viracta Therapeutics, Inc.
VIRXNASDAQCommon stockHistorical · closed Feb 2, 2025CIK 1061027Updated Sep 27, 2026
Name history
SUNESIS PHARMACEUTICALS INC · through Mar 2, 2021
VIRX price & chart
Historical security
This listing closed Feb 2, 2025. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
25-NSE - filed by Nasdaq Stock Market LLC regarding Viracta Therapeutics, Inc.
SCHEDULE 13G - filed by FORWARD VENTURES V LP regarding Viracta Therapeutics, Inc.
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.05, 5.02, 8.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Entry into a Material Definitive Agreement · Triggering Events That Accelerate or Increase a Direct Financial Obligation
Items 1.01, 2.04, 9.01
Show 5 more recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 56,692,000Source | 95,991,000Source | 108,552,000Source | 23,247,000Source |
| Property, Plant and Equipment, NetUSD | 190,000Source | 148,000Source | 242,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,317,000Source | 36,773,000Source | 103,554,000Source | 20,410,000Source |
| Assets, CurrentUSD | 54,964,000Source | 93,747,000Source | 105,273,000Source | 22,144,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,273,000Source | 2,704,000Source | 1,719,000Source | 1,734,000Source |
| Operating Lease, Right-of-Use AssetUSD | 274,000Source | 266,000Source | 640,000Source | 273,000Source |
| Other Assets, NoncurrentUSD | 1,264,000Source | 1,830,000Source | 2,397,000Source | 830,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 38,373,000Source | — | — | 3,310,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 5,452,000Source | 5,452,000Source | 5,452,000Source | 5,545,000Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 4,000Source | 4,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 278,786,000Source | 270,699,000Source | 254,592,000Source | 718,800,000Source |
| Retained Earnings (Accumulated Deficit)USD | -265,932,000Source | -214,874,000Source | -165,677,000Source | -704,410,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 9,000Source | -178,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 18,319,000Source | 61,103,000Source | 94,371,000Source | 19,937,000Source |
| Liabilities and EquityUSD | 56,692,000Source | 95,991,000Source | 108,552,000Source | 23,247,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 38,373,000Source | 10,011,000Source | 9,084,000Source | 3,310,000Source |
| Operating Lease, Liability, CurrentUSD | 282,000Source | 278,000Source | 381,000Source | 273,000Source |
| Accounts Payable, CurrentUSD | 2,441,000Source | 2,540,000Source | 2,901,000Source | 479,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 278,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 10,376,000Source | 7,193,000Source | 5,802,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 53,700,000Source | 91,000,000Source | — | — |
| Long-term Debt, Current MaturitiesUSD | 25,274,000Source | — | 0Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 24,877,000Source | 4,819,000Source | — |
| Short-term InvestmentsUSD | 41,374,000Source | 54,270,000Source | — | — |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -21,610,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 492,000Source | 210,000Source | 178,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,649,000Source | 13,548,000Source | 5,542,000Source | 1,324,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -98,000Source | -361,000Source | 922,000Source | -312,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -39,892,000Source | -35,457,000Source | -18,851,000Source | -21,439,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 14,998,000Source | -53,866,000Source | 12,891,000Source | 16,407,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 138,000Source | 45,000Source | 252,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 438,000Source | 22,542,000Source | 62,425,000Source | 7,181,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | 2,149,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 12,317,000Source | 36,773,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,070,000Source | 454,000Source | 343,000Source | 339,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 7,649,000Source | 13,548,000Source | 5,542,000Source | 1,324,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | 35,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 53,700,000Source | 91,000,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | 0Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | -41,000Source |
| General and Administrative ExpenseUSD | 17,324,000Source | 24,327,000Source | 15,437,000Source | 10,164,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -51,058,000Source | -49,197,000Source | -114,762,000Source | -21,610,000Source |
| Operating ExpensesUSD | 50,693,000Source | 50,589,000Source | 127,776,000Source | 22,423,000Source |
| Operating Lease, ExpenseUSD | 400,000Source | 400,000Source | 608,000Source | — |
| Other Nonoperating Income (Expense)USD | -365,000Source | 1,392,000Source | -486,000Source | 995,000Source |
| Proceeds from Issuance of Common StockUSD | 299,000Source | 2,331,000Source | 62,320,000Source | 12,633,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 187,000Source | -178,000Source | — | — |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 120,000Source |
| Operating Income (Loss)USD | -50,693,000Source | -50,589,000Source | -114,276,000Source | -22,303,000Source |
| Other Nonoperating Income (Expense)USD | -365,000Source | 1,392,000Source | -486,000Source | 995,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -21,609,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -51,058,000Source | -49,197,000Source | -114,762,000Source | -21,610,000Source |
| Earnings Per Share, BasicUSD per share | -1.32Source | -1.3Source | — | — |
| Earnings Per Share, DilutedUSD per share | -1.32Source | -1.3Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 38,624,462Source | 37,790,981Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 38,624,462Source | 37,790,981Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 17,324,000Source | 24,327,000Source | 15,437,000Source | 10,164,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | -21,609,000Source |
| Interest and Other IncomeUSD | 3,344,000Source | — | — | — |
| Interest ExpenseUSD | 3,704,000Source | 577,000Source | 491,000Source | 302,000Source |
| Interest Income, OtherUSD | 3,345,000Source | 1,171,000Source | 38,000Source | — |
| Operating ExpensesUSD | 50,693,000Source | 50,589,000Source | 127,776,000Source | 22,423,000Source |
| Operating Lease, ExpenseUSD | 400,000Source | 400,000Source | 608,000Source | — |
| Other ExpensesUSD | — | — | 290,000Source | — |
| Research and Development ExpenseUSD | — | — | — | 12,259,000Source |
Filing attachments
virx-ex99_1.htm · 8-K · 2025-02-05
EX-99.1 2 virx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Viracta Therapeutics Announces Wind Down of Operations SAN DIEGO, February 5, 2025 - Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its de…
Read attachment ↗